Sitemap
- Home
- Diabetes
- Integrated Diabetes Care
- Articles
- The InRange Study
- New technologies in Type 2 Diabetes management and future opportunities to improve clinical outcomes
- Challenges associated with commonly-used insulin advancement options
- Do historical HbA1c values explain glycemic legacy effect in type 2 diabetes?
- Time-In-Range (TIR): How to interpret it and how it is associated with outcomes
- Diabetes management during Ramadan
- Patient awareness and attainment of goals in Type 2 Diabetes Mellitus: A real-world survey
- Time-in-Range: A Key Determinant of Quality of Life
- What Is Time-in-Range?
- Management of athletes and active people with diabetes - The American Medical Society for Sports Medicine (AMSSM) scientific statement
- Groundbreaking SoliD Study: Comparative Efficacy of iGlarLixi and IDegAsp
- EMPOWER Study in Saudi Arabia
- The Evolving Role of Treatment and Technology in Diabetes Care
- Need to redefine the treatment paradigm Post OAD
- Expert consensus statement on management of older adults with type 2 diabetes (T2D)
- EVOLUTION: RWE from Saudi Arabia
- Unveiling Significance of Time in Range: Value as key Glycemic Biomarker
- Understanding Time-in-Range: Assessment, Targets, and Benefits for Optimal Glycemic Control
- ATTD 2021: Patients’ profiles for digital tools
- Post-exercise hypoglycemia in relation to medication regimen among adults with type 2 diabetes
- A narrative review for clinicians on insulin management for Type 2 Diabetes during Ramadan
- Impact of Time-In-Range on Diabetes Management
- Resources
- Tools
- Articles
- Other Diabetes Topics
- Type 2 Diabetes
- Articles
- New Horizon in management of high-risk patients with Diabetes
- iGlarLixi Enables Safe Ramadan Fasting for Most T2D Patients
- Recommendations on treatment simplification of complex insulin regimens to improve clinical outcomes in patients with T2DM
- Glargine 300 use in people with type 2 diabetes who fast during Ramadan
- Advancing Therapy with iGlarLixi: Differentiation from other complex regimens
- New 2022 ADA/EASD Guidelines: GLPP-1 RA/Insulin Combination Is Recommended
- ATTD 2021: Technology Supporting Initiation, Titration, and Intensification
- SoliD: Redefine Treatment Paradigm Post-OAD
- The ATOS Study: Real-World Study on Effectiveness of Insulin Glargine U300 in the Gulf Region.
- The SoliRam observational study
- SoliMix Study Results Summary
- Advancing therapy in suboptimally controlled basal insulin-treated type 2 diabetes: Clinical outcomes with iGlarLixi versus premix BIAsp 30 in the SoliMix randomized controlled trial.
- Effective Treatment Simplification
- Is Premixed Insulin an Effective Treatment for Type 2 Diabetes Uncontrolled by OADs?
- Articles
- Type 1 Diabetes
- Articles
- The burden of Autoimmune T1D
- Summary of SAGE study on Adults with T1DM
- Inside Diabetes: ATTD Edition | Type 1 Diabetes
- Saudi Health Promotion and Prevention Guideline for Diabetes Mellitus
- Understanding Autoimmune T1D disease & Different Stages
- How to screen for Autoimmune T1D
- Edition Junior Study - Helping patients with type 1 diabetes (T1D) to find better treatment options
- Why to screen for Autoimmune T1D
- Closed-loop insulin delivery during exercise in people with T1DM
- Articles
- Integrated Diabetes Care
- Dermatology
- Atopic Dermatitis
- Articles
- Can Early Intervention Shape the Course of Atopic Dermatitis
- Type 2 Inflammation in Skin Tissue: Exploring Shared and Distinct Pathways in Prurigo Nodularis and Atopic Dermatitis
- Improving Quality of Life in Patients with Uncontrolled Atopic Dermatitis (AD): Tools for Timely Identification and Treatment
- Disease Modification Concepts in Atopic Dermatitis
- Can Early Therapeutic Intervention Shape Disease Course in Pediatric AD
- Inside Atopic Dermatitis: Burden on Patients
- Association of Younger Age of Onset with Persistence of Atopic Dermatitis
- Unseen Burdens: How Cumulative Life Course Impairment (CLCI) Affects Patients with Moderate-to-Severe Atopic Dermatitis (AD)
- Atopic Dermatitis in Children: High Burden and Limited Treatment Options
- The Cumulative Disease Burden of AD in Adult Patients
- Long-Term-Impact-of-AD-and-the-Potential-benefits-of-early-intervention
- Mechanism of Action of Atopic Dermatitis
- AD and PN: Diagnosis and Impact on Quality of Life
- What Could Remission Mean in Atopic Dermatitis
- The Hidden Impact of Cumulative Life Course Impairment (CLCI) in Dermatology: An Overview
- Inside Atopic Dermatitis: Burden on the Healthcare System
- Factors Associated with Development of Atopic Comorbidities in AD
- Impact of Advanced Systemic Therapies on Disease Control in AD
- The role of Epithelial Barrier Components in AD, insights and implications
- Understanding Cumulative Disease Burden in Uncontrolled AD
- IL4 and IL13 important role in Chronic Itch
- Tools
- Events
- Articles
- Prurigo Nodularis
- Articles
- Type 2 Inflammation may play a role in Prurigo Nodularis Pathophysiology¹
- Mechanism of Prurigo Nodularis Disease
- PN Expert Interview Series with Dr. Shawn Kwatra
- There is significant unmet need in the management of PN¹
- Practical Approach in Understanding PN Pathophysiology
- Dupilumab in patients with prurigo nodularis: two randomized, double-blind, placebo-controlled phase 3 trials
- The Pathophysiology of Prurigo Nodularis
- Prurigo Nodularis is a distinct, Chronic, Neural and Immune- Mediated skin disease characterized by intense itch and Nodular Lesions¹
- Events
- Articles
- Bullous Pemphigoid
- Chronic Spontaneous Urticaria CSU
- Atopic Dermatitis
- Cardiology
- Other Cardiology Topics
- Resources
- 556/146 for Lipid Management after ACS
- How to Inject Praluent 300mg prefilled pen
- Are You Ready for 556? Achieving Critical LDL-C Targets
- Why Praluent is the Optimal Choice for Post-ACS Patients?
- Understanding the 556/146 Concept: Insights from Leading Experts
- How to Inject Praluent Once-Monthly 300 mg Pen?
- Act Now for your ACS Patients
- How to Inject Praluent 75/150 mg Pen?
- Exploring the 556/146 Concept: Insights from Leading Experts
- Are You Ready for 146? Achieving Optimal LDL-C Levels
- Resources
- Dyslipidemia
- Articles
- Improving Lipid Management for Patients Post-ACS
- Approach for Patients with CAD: Focus on LDL-C Control
- PCSK9i after hospital discharge for acute MI
- Overview of adherence data with LLT highlighting the most recent data with PCSK9i
- Lipid management in patients with ACS/ASCVD
- Relationship Between LDL-C LLTs and Risk of Stroke
- Act Now for Your ACS Patients: Summary
- Lp(a) as ASCVD risk factor
- Act Now for Your ACS Patients: Patient Identification
- ACC/AHA vs ESC/EAS LDL–C recommendations for residual risk reduction in ASCVD: A simulation study from Da Vinci
- Prospective evaluation of lipid management following ACS in Saudi Arabia (ACOSYM Study)
- Cardiovascular diseases (CVDs) are the leading cause of death globally¹
- PCSK9i and Prevention of CVD
- Act Now for Your ACS Patients: Treat Aggressively, Combine and Start Early
- Atherosclerotic Cardiovascular Disease Risk Assessment
- Possible Challenges Post One Year of ESC/EAS Guidelines
- Approach for Patients with PAD and T2D: Focus on LDL-C Control
- The role of the patient in Achieving LDL-C Target
- Act Now for Your ACS Patients: Optimize Your ACS Pathway
- Identifying and treating patients with high Lipidaemia risk post-ACS
- Atherosclerosis: Identifying risks and improving outcomes
- Public health recommendations for Lp(a) measurement
- Lipid Management in Patients with Diabetes Mellitus
- Resources
- Events
- Articles
- Thrombosis
- Articles
- Changing trends in VTE: Pulmonary Embolism cases on Rise within the Last Decade
- Specific Patient Characteristics Linked to Below Average Quality of Life in Patients with Recent Venous Thromboembolism (VTE)
- Effect of de-escalated P2Y12 inhibitor switching in dual antiplatelet therapy (DAPT)
- Caprini Score Responses to Prevent VTE in Patients Undergoing Varicose Vein Surgery
- VTE Prophylaxis in Surgical Patients
- 2019 ESC Guidelines for Acute Pulmonary Embolism
- Utility of Pregnancy - Adapted Years Algorithm in Diagnosis of Pulmonary Embolism
- Benefit of Prophylaxis for High-Risk Surgical Patients
- Evaluation Of Comparative Efficacy and Safety of Thromboprophylaxis Agents Among Critically Ill Patients
- Risk for Pulmonary Embolism Continues Beyond 6 Weeks of Surgery
- Prolonged Thromboprophylaxis with LMWH after Abdominal or Pelvic Surgery
- Risk for Post-operative Venous Thromboembolism in Patients Receiving Enoxaparin Prophylaxis
- VTE Comparison of Pregnancy - Specific Risk Scoring Systems in Hospitalized Maternity Patients
- Trends in Pulmonary Embolism-related mortality in Europe
- Maternity Clot Risk Model to Predict Women at Risk of VTE
- Global use of RAM and Thromboprophylaxis in hospitalized patients
- Independent Risk Factors for Venous Thromboembolism
- Events
- Articles
- Hypertension
- Other Cardiology Topics
- Vaccines
- Respiratory Syncytial Virus
- Articles
- Burden of Disease
- RSV History
- All Infant Protection
- RSV Burden in Infants
- Beyond High-Risk: Expanding RSV Protection for Newborns and Infants
- Saudi initiatives on Bronchiolitis Recommendations
- RSV Burden in Jazan
- Real-World Effectiveness of Nirsevimab: Evidence from the NIRSE-GAL Study
- Nirsevimab RWD Metanalysis
- New horizon of RSV lower respiratory tract disease LRTD in infants: Reflection on two seasons of prevention
- RSV
- Ensuring overall RSV prevention in every individual Dr. Alia Podcast
- RWE data on Nirsevimab and RSV preF vaccine
- Kuwait taking the lead in RSV protection for all infants in the Middle east
- Rattle
- Healthcare Utilization and Economic Burden of RSV Infections Among Children Under 5 Years in Saudi Arabia: A MNGHA Facilities Analysis
- Implementing Beyfortus successfully
- Nirsevimab FAQs
- Resources
- Articles
- Influenza
- Mass Gathering
- Respiratory Syncytial Virus
- Rare Disease
- Other Rare Disease Topics
- Articles
- Extraordinary measures: what are the benefits to have such movies talking about Rare Diseases?
- What are Lysosomal Storage disorders?
- The role and importance of Patients Associations and Scientific societies ; Oman Experience
- Pompe don’t lose time video
- How To Diagnose LSDs?
- Legacy Video for Rare Disease Academy
- Multidisciplinary approaches in Rare Disease Patient management
- Lysosomal Storage Diseases from Neurology Perspective
- What is the role of Artificial Intelligence in accelerating patient's diagnosis?
- The Stigma of Rare Diseases
- LSDs overview
- An overview of Lysosomal Storage Disorders & Sanofi`s Commitment to the Development and Provision of Treatments
- When shall we think of a rare disease from Neurological perspective
- The role and importance of Patients Associations and Scientific societies ; UAE experience
- Every Moment Matters: Navigating Diagnosis of Fabry Disease
- Multidisciplinary approaches in Rare Disease Patient management in KSA
- Meet a Sanofi Specialist
- What are the new diagnostics modalities used to expedite Rare Disease patients identification?
- Resources
- Articles
- Pompe
- Articles
- The Many Faces of Limb-Girdle Weakness
- Prevalence of LOPD in patients with undifferentiated proximal myopathy and undiagnosed muscle biopsy
- Long-term Safety and Efficacy of Avalglucosidase Alfa IN Patients with Late-Onset Pompe Disease (NEO-EXT)
- Differential Diagnosis Of Late Onset Pompe Disease (LOPD) and Myotonic Dystrophy Type 1 Through Abdominal Ultrasonography
- Have you considered Pompe Disease?
- Expert Group Consensus From the Arabian Peninsula On the Diagnosis of Lopd
- Diagnostic challenges of LOPD
- Their Stories shaped them like Pearls
- Pompe video
- Expert group consensus from the Arabian Peninsula on the diagnosis of Late Onset Pompe Disease (LOPD)
- Early diagnosis and management of IOPD
- IOPD Challenges
- Pompe
- Safety and efficacy of Avalglucosidase Alfa versus Alglucosidase Alfa in patints with Late-Onset Pompe Disease (COMET): a phase 3, randomized, multicentral study results
- Pompe Care Podcast Series
- When Weakness Tells a Bigger Story
- Navigating the Pompe Disease Journey
- Expert Group Consensus From The Arabian Peninsula On The Diagnosis Of Late Onset Pompe Disease for orthopedists
- Expert Group Consensus From the Arabian Peninsula On the Diagnosis of Lopd
- Experts recommendations on Late Onset Pompe Disease (LOPD) differential diagnosis from GCC
- Resources
- Articles
- Gaucher
- Articles
- Gaucher disease awareness month video
- Bone Monitoring Guidelines in Gaucher Disease Video
- The Role of Pediatrician in Gaucher Disease
- Understanding Gaucher Disease Type 3
- Gaucher Haematology Diagnosis support
- Gaucher Mechanism of Disease
- Diagnostic Algorithm for Gaucher Disease in Pediatric
- When Hematological Signs Lead the Diagnosis
- Diagnostic Algorithm for Gaucher Disease in Adult
- Gaucher Biochemistry Diagnosis support
- Diagnosis of Gaucher disease
- Gaucher Neurology Diagnosis support
- The Enlarged Spleen Mystery
- Resources
- Events
- Articles
- Fabry
- Articles
- When the Heart, Kidneys, and Nerves Intersect
- Fabry Disease in Cardiology Practice: From Red Flags to Diagnosis
- BIOCHEMICAL DIAGNOSTIC STRATEGY IN FEMALES SUSPECTED OF FABRY DISEASE
- Fabry
- Role of Ecg in Differential Diagnosis of Anderson - Fabry Disease with HCM
- Tolerability of Accelerated Agalsidase Beta Infusions in Fabry Disease: The SHORTEN Study Analysis
- From Registry to Reality: Reduced Stroke Incidence with Agalsidase Beta in Fabry Disease
- Renal Outcomes After Switching to Agalsidase Beta: A Single-Center Analysis
- Fabry Disease from Cardiology Perspective
- Better care for Fabry
- Structured Monitoring for Early Detection of Fabry Progression
- DIAGNOSING FABRY DISEASE IN CLINICAL PRACTICE
- Resources
- Events
- Articles
- Mucopolysaccharidosis Mps
- Acid Sphingomylenase Deficiency Niemann Pick
- Articles
- Professor Moeen Al Sayed video on ASMD
- Impact of symptoms and risk of ASMD on patients and caregivers
- What is ASMD?
- Management of ASMD - Expert opinion: Professor Fatma Al- Jasmi
- Differential diagnostics for ASMD in patients suspected to have GD
- Professor Fatma Al-Jasmi video on ASMD
- ASMD Phenotypes
- How do you know if you or a loved one has ASMD?
- Consensus Guidelines for the Clinical Management of ASMD
- Management of ASMD - Expert opinion: Professor Tawfeq Ben Omran
- Professor Tawfeq Ben Omran video on ASMD
- What Are the Signs and Symptoms of ASMD?
- ASMD
- Management of ASMD - Expert opinion: Professor Moeen Al Sayed
- Uncover ASMD and GAUCHER
- Inspiring Stories of Patients Living with ASMD
- Respiratory Impairment in Acid Sphingomyelinase Deficiency (ASMD): A Case Report.
- How is ASMD inherited?
- Events
- Articles
- Lysosomal Storage Disorders (LSD)
- Other Rare Disease Topics
- Neurology
- Multiple Sclerosis
- Articles
- Tolebrutinib Direct Effects on Myeloid Cells in PwMS
- Why has our brain suddenly become of interest?
- Measuring brain atrophy. What can be done and where are we heading?
- Understanding Kaplan–Meier Curves in MS: An Overview with Dr. Barry Singer
- Inside MS: Explore how BTK drives immune cell activation and CNS damage
- Understanding PIRA in MS: An Overview with Dr. Barry Singer
- MS Updates
- Falling chronically ill – How do I cope and move forward?
- Cognitive training – A curse or a blessing?
- Smoldering Neuroinflammation
- Thalamic atrophy as a new biomarker of MS? The predictive value and how to use in clinical practice
- A promising biomarker in MS: Neurofilament light chain
- Learning aRMMs
- The Role of the CNS and Periphery in MS and Disease Accumulation
- Exercise as ”medicine” in the treatment of MS
- How old is your brain?
- Cognitive decline – The invisible burden of MS?
- Discover the science behind Tolebrutinib: a BTK inhibitor designed to slow MS disability progression by modulating adaptive and innate immunity
- The reason for MS – beyond focal inflammation
- The importance of deep grey matter in MS
- Understanding 6‑Month CDP in MS: An Overview with Dr. Barry Singer
- Events
- Advancing the Standard of Care: Addressing Progression in MS
- MS pulse - Tracking the hidden drivers of MS progression
- Intro to Multiple Sclerosis by Dr Naji Riachi
- A Patient's Journey on Teriflunomide: insights into Long-Term Treatment
- MSXChange l MS and Women
- Multiple Sclerosis Diagnosis and Misdiagnosis by Prof. Bassem Yamout
- Aubagio® - Impact on Brain Health and Real World Efficacy by Dr. Ahmed Shatila
- Personalized Therapy in RMS - Which DMT to Use and When? Professor Peter Rieckmann
- The Underlying Biology of Neuroinflammation
- Articles
- Epilepsy
- Multiple Sclerosis
- Rare Blood Disorders
- Respiratory
- Chronic Obstructive Pulmonary Disease (COPD)
- Articles
- What tests can help diagnose and monitor your patients with COPD?
- A deeper look at the inflammation behind exacerbations can IGNITE NEW THINKING IN COPD
- A deeper look at the inflammation behind exacerbations in COPD
- (COPD): Disease Burden and Heterogeneity
- Type 2 Inflammation in the Pathophysiology of the Lower Airways
- GOLD Recommendations for Treatment and Management of COPD
- GOLD 2026 Report: Key Updates for COPD Management
- Clinical Indicators of COPD: A GOLD Guidelines Review
- Articles
- Asthma
- Articles
- Consider Dupixent for Asthmatic patients with OCS use
- Dupixent® (dupilumab) Mechanism of Action
- IL-4/IL-13 Dual Cytokine Signaling in Severe Asthma: Mechanistic Insights by Prof. Kenneth Chapman
- The Vital Role of Lung Function in Asthma Care
- Understanding Airway Obstruction: The Role of Mucus Plugging in Asthmatic Disease
- Asthma Clinical Remission: The Benchmarks for Eliminating Airway Inflammation and Symptoms
- Consider Dupixent for Asthmatic patients with high EOS
- Discover a solution to control mixed Eosinophilic and Allergic Asthma
- VESTIGE Trial Results: Dupilumab in Type 2 Asthma
- Fractional exhaled nitric oxide (Feno)
- Mucus Plugging Is a Key Component of Remodeling in Asthma, Leading to Fixed Airway Obstruction
- Sever Asthmatic patients with OCS
- Airway Hyperresponsiveness in Asthma
- Pediatric Management
- FeNO Is a Clinically Useful Biomarker of Type 2 Inflammation in Pediatric Patients With Asthma
- What is your experience with Dupixent in your practice?
- ON-TREATMENT ASTHMA REMISSION: MOVING BEYOND CONTROL
- Severe Asthma Biomarker's
- VESTIGE study
- IL-4, IL-13, AND IL-5 ARE DRIVERS OF SYSTEMIC TYPE 2 INFLAMMATION
- What gives you confidence that Dupixent improves patients’ quality of life?
- About Type 2 Inflammation – Asthma
- Articles
- Chronic Obstructive Pulmonary Disease (COPD)
- Oncology
- Multiple Myeloma
- Articles
- Experts Perspective
- Lenalidomide Refractory Patients
- Myeloma Facts
- Patients Factors & Impacts
- Importance of MRD
- Multiple Myeloma: Elderly Patients
- About MRD
- Multiple Myeloma: Renal Impairment
- Transform Myeloma
- The Future of MRD
- Multiple Myeloma: Chromosome 1q+ cytogenetic abnormalities
- Multiple Myeloma: High Risk Cytogenetics
- Multiple Myeloma: Minimal Residual Disease
- Minimal Residual Disease
- True Cost of Multiple Myeloma
- MRD FAQs
- Articles
- Multiple Myeloma
- Rhinology
- Chronic Rhinosinusitis With Nasal Polyps Crswnp
- Articles
- "It really has changed the way I manage our patients"
- “Smell—we call it the Cinderella of the senses"
- IL-4 and IL-13 are key and central cytokines with unique and overlapping roles contributing to the pathophysiology of CRSwNP
- Rethink your Nasal Polyps. Type 2 Inflammation a Nasal Polyp mystery
- Management of ALLERGIC FUNGAL RHINOSINUSITIS (AFRS): A sever type 2 Inflammatory Disease
- EPOS2020/EUFOREA Expert Opinion on Defining Disease States and Therapeutic Goals in CRSwNP
- How does Dupixent help recover smell?
- NPS improvement with Dupixent over time
- What can biologic treatment do for patients with CRS with nasal polyps?
- Hear from an expert on how do you address Patients' concerns about Sinus surgery?
- Hear from an expert on how can you limit the effects of systemic steroid use for Patients with CRS with Nasal Polyps?
- Hear from an expert on what does Dupixent bring to your practice?
- About Type 2 Inflammation – Nasal Polyps
- Hear from an expert on would you consider a biologic for a Surgery-naïve Patient with CRS with Nasal Polyps?
- Hear from an expert on how does Dupixent target Underlying Type 2 Inflammation?
- Expert opinions: Would you consider a biologic for a CRSwnp patient who has had Sinus surgery?
- Loss of Smell Improvement in Patients With CRSwNP
- Daily Burden of CRSwNP
- Look beyond the symptoms to identify and manage Patients with Type 2 Inflammation
- Loss of Smell Is a Key Symptom in CRSwNP
- Hear From An Expert On The Type 2 Immune Response And Inflammation
- Hear from an expert on what have you learned from your experience with biologics?
- Hear from an expert on how do you manage treatment compliance issues in Patients with CRS with Nasal Polyps?
- What does patient empowerment mean for your treatment plan?
- Hear from an expert on Identifying Patients who are appropriate candidates for Biologic treatment
- Type 2 Inflammation is the underlying cause of CRSwNP in 80% of Patients.
- Hear from an expert on what are the main challenges in treating Patients with CRS with Nasal Polyps?
- Hear From An Expert On What Does The Future Of Treatment Look Like For Crs With Nasal Polyps?
- You can imagine more than 90% of CRSwNP patients losses their ability's of smell
- Pneumology Meets Oto-Rhino-Laryngology: A Discussion of Type 2 Inflammation in Airway Diseases
- Articles
- indications.allergic_fungal_rhinosinusitis
- Chronic Rhinosinusitis With Nasal Polyps Crswnp
- Other topics
- Payor
- Articles
- Rezurock Economic Value
- Burdens of CSU
- Unmet Needs
- Unmet Need
- Tzield Efficacy and Safety
- Rezurock Safety
- AT1D Early Detection
- Proven Efficacy of Dupixent® in COPD
- Clinical Burden of COPD
- Tzield MOA and Dosing
- Burden of Disease
- Proven Safety of Dupixent® against Type 2 Inflammation
- cGVHD Burden
- Disease Overview
- Proven Efficacy of Dupixent® against Type 2 Inflammation
- Rezurock Dosage
- Economic Burden of COPD in UAE
- Rezurock Efficacy
- Articles
- Other topics
- Immunology Pipeline
- Payor
- Transplant
- chronic GRAFT-VERSUS-HOST DISEASE (cGVHD)
- Articles
- Inflammation and Fibrosis Role
- European Respiratory Society (ERS)/ European Society for Blood and Marrow Transplantation (EBMT) clinical practice guidelines on treatment of pulmonary cGvHD in adults
- Impact on Patients
- Between The Lines: GVHD, Episode 2–Skin Manifestation of GVHD – A multidisciplinary Perspective
- Tandem Meetings Transplantation and Cellular Therapy Meetings of ASTCT® and CIBMTR®
- The Congress Connection: cGvHD and Transplant Key Takeaways in 2025
- Understanding cGVHD
- Updated European Society of Blood and Marrow Transplantation consensus recommendations for GVHD prophylaxis and management in hematological malignancies after stem-cell transplantation
- Advances in the biology of chronic GVHD
- TANDEM Meeting 2026
- Treatment under Clinical Development
- Between The Lines: GVHD, Episode 1 – Understanding the Foundation of Graft vs Host Disease
- Molecular Pathway
- Clinical outcomes of cGvHD following allogeneic HSCT: A Swedish population-based real-world registry study
- Other Treatment Options
- Optimizing Treatment
- GvHD in Focus Risk Factors and Symptoms
- Psychological & Economical impact
- Articles
- Transplant
- chronic GRAFT-VERSUS-HOST DISEASE (cGVHD)
- Gastroenterology
- Eosinophilic esophagitis
- Articles
- EOE Pediatric - Unmasking the Hidden Symptoms
- Pediatric EoE: Indicators for Early Diagnosis and Intervention
- EoE Pathophysiology
- Understanding Eosinophilic Esophagitis (EoE)
- Importance of assessing key disease domains in EOE
- Measures of Disease Severity in Eosinophilic Esophagitis (EoE)
- Adaptive Eating Behaviors in EoE
- EoETaly Guidelines Part-2
- EoETaly Guidelines Part-1
- Dupilumab in Pediatric EoE: Phase 3 KIDS Study Results
- Articles
- Eosinophilic esophagitis
- Hematology
- Products
- Nexviazyme®
- WAYRILZ (rilzabrutinib)
- Fabrazyme®
- Lemtrada®
- Dupixent® COPD
- Soliqua®
Post-GLP Podcast: needs of patients on GLP-1 RA with basal insulin
- Soliqua SoliD®
- iGlarLixi vs basal plus rapid-acting insulin in adults with type 2 diabetes advancing from basal insulin therapy: The SoliSimplify real-world study
Soliqua Unmet Needs Video
Limitations of Premixed Insulin
- Soliqua Guidelines®
Meet the Expert
- SOLIQUA® Easy start
- Soliqua Safety®
- Soliqua®
- Soliqua Data Set®
Reimbursement
- For a Peaceful Ramadan
- Soliqua Simplicity®
- Qfitlia®
QfitliaTM (fitusiran): ATLAS clinical trial design
Qfitlia HCP Bleed Management Guidance (BMG)
Dosing for Qfitlia™ (fitusiran) is guided by antithrombin levels1
Qfitlia AT Measurement and Dosing Guide
Safety information and adverse events on QfitliaTM (fitusiran)
Qfitlia Prescriber Safety Brochure
INTERACTIVE DOSING TOOL FOR QFITLIATM
Manage breakthrough bleeds with reduced doses and frequency of factor or BPA1*†
QfitliaTM (fitusiran) offers proven bleed protection with as few as 6 injections a year1
Mechanism of action: how QfitliaTM (fitusiran) helps restore hemostasis by lowering antithrombin for people with hemophilia1
- Dupixent® Eosinophilic Esophagitis
- Aldurazyme®
- Xatral®
- Dupixent® Atopic Dermatitis
- Clexane®
- Sarclisa®
IMROZ: the only trial to evaluate an anti-CD38 +VRd therapy in 100% transplant-ineligible population.
GMMG-HD7: the first phase 3 trial to assess the value of adding an anti-CD38 to VRd for induction alone, regardless of maintenance
Mechanism of Action
Dosing & Administration
ICARIA-MM: Addition of SARCLISA to Pd Extended Median PFS to Nearly 1 Year
IKEMA: mPFS of 3 years with SARCLISA + Kd is longest ever reported for anti-CD38 therapy in a pivotal trial that included lenalidomide-refractory patients
- Dupixent® Nasal Polyps
- Adacel®
- Tzield®
- Dupixent® Chronic Spotaneous Urticaria (CSU)
- Dupixent® Prurigo Nodularis
- Cablivi®
- aTTP-Related Events
- aTTP Sphere Digital Case Library
- Platelet Count Normalization
- CABLIVI Safety Profile
- Mechanism of Disease
- Early Treatment Initiation
- Delay in CABLIVI Start - Patient Outcomes
- Healthcare Resource Utilization
- aTTP Sphere Digital Case Library - Kuwait
- Delay in CABLIVI Start
- Real-World Evidence Studies
- TTP Patient Case Study in UAE by Dr Hani Osman
- HERCULES: Summary2
- TTP Patient Case Study in UAE by Dr Hasan
- aTTP Diagnosis and Treatment
- REACT-2020 and Aggregated Analysis
- ISTH TTP Guidelines
- Active Disease
- Real World Evidence Studies/Italian
- Post-HERCULES
- CABLIVI Mechanism of Action
Watch ITTP patient shares his road to diagnosis of TTP and how healthcare professionals can further help patients and care partners
- HERCULES STUDY
- ISTH TTP Guidelines
- CABLIVI-Specific Treatment Recommendation1
- aTTP Sphere Digital Case Library - Qatar
- Real World Evidence Studies/Spanish
- CNR-MAT Registry Study
- Recurrences
- HERCULES Study
- TTP Patient Case Study in KSA
- Cerezyme®
- Dupixent®
- Toujeo®
Timely insulin initiation to limit disease progression
- Guidelines
Second generation basal insulin in advancing T2D therapy
- Type-1 Meta Analysis
Meet the Expert
- Edition Junior
- To help you manage your patients with T1DM
- OneCare
- Toujeo T2DM
- Guidelines
- How to Start
- UltraFlexi-1
- Efficacy & Tolerability
- Innovation
- Wall of Evidence
- Toujeo for a Peaceful Ramadan
- Deliver-G
- Beyfortus®
International Recommendation
Beyfortus in Action: Real-world data from the 2023-2024 RSV season
Decoding RSV unveiling truths and myths in infant burden
Beyfortus, an innovative immunization for RSV disease prevention in infants
Beyfortus®, an innovative immunization for RSV disease prevention in infants
Implementing Beyfortus successfully: Practical insights from Spain
Clinical Experience
Conferences
Real world evidence
Nirsevimab International Recommendation
- Xenpozyme®
- Aubagio®
- Myozyme®
- Rezurock®
- Influenza
- Td Ipv Booster
- Hunter Syndrome
- Other Diabetes Topics
- indications.acromegaly
- Polio
- indications.psoriatic_arthritis
- Immune Thrombocytopenic (ITP)
- Hemophilia B
- Arrhythmia
- Chronic Spontaneous Urticaria CSU
- Chronic Rhinosinusitis With Nasal Polyps Crswnp
- Cold Agglutinin Disease (CAD)
- Other Vaccines Topics
- indications.allergic_rhinitis
- indications.gastric_adenocarcinoma
- General Topics
- indications.analgesics
- Hypertension
- Tetanus
- Multiple Myeloma
- Immunology Pipeline
- indications.blood_cancer
- chronic GRAFT-VERSUS-HOST DISEASE (cGVHD)
- Hepatitis A
- Atopic Dermatitis
- Dtacp Hib Ipv Hep B Hexa Acellular Primary Series
- Dyslipidemia
- Chronic Kidney Disease Ckd
- Benign prostatic hyperplasia (BPH)
- Coronavirus Disease 2019
- Diphtheria
- Type 2 Diabetes
- Rabies Immunoglobulins
- Cholera
- indications.griep
- indications.airway_mucus_hypersecretion
- Hepatitis A Typhoid
- Biosurgery
- Academy of Knowledge
- Dtwcp Hib Hep B Penta Whole Cell Primary Series
- Other Rare Disease Topics
- indications.anesthetic
- Thrombosis
- GM2 Gangliosidosis
- Injectable Polio Vaccine
- Epilepsy
- indications.myasthenia_gravis_mg
- indications.angina
- Dtacp Hib Ipv Penta Acellular Primary Series
- Eosinophilic esophagitis
- Hepatitis B
- Anti Inflammatory
- Gaucher
- indications.parkinson’s_disease_pd
- Payor
- Heart failure
- Rheumatoid Arthritis
- Oral Polio Vaccine
- Corticosteroids
- Hemophilia
- Rabies
- Flu Seasonal Standard Dose
- Tetanus Booster
- indications.renal_disease
- Acellular Pertussis
- Fabry
- Dengue
- Acquired Thrombotic Thrombocytopenia Purpura aTTP
- Anxiety
- Central nervous system
- Hypothyroidism
- Thyroid Cancer
- Dtacp Ipv Tetra Acellular Primary Series
- Bipolar
- Cardiac Stimulants
- Hemophilia A
- Hypnotics
- indications.neuroendocrine_tumors
- Solid Tumor Malignancies
- indications.chronic_inflammatory_demyelinating_polyneuropathy_cidp
- Other Neurology Topics
- indications.cervical_cancer
- Other topics
- Breast Cancer
- Diphteria Tetanus Booster
- indications.neutrophil_deficiency
- Asthma
- Other Transplant Topics
- Dtacp Tri Acellular Primary Series
- Prurigo Nodularis
- indications.urticaria
- Pompe
- indications.tuberculosis_test
- Multiple Sclerosis
- Japanese Encephalitis
- Integrated Diabetes Care
- Bullous Pemphigoid
- Polymyalgia Rheumatica (PMR)
- Chronic Obstructive Pulmonary Disease (COPD)
- Acid Sphingomylenase Deficiency Niemann Pick
- Skin Cancer
- Mucopolysaccharidosis Mps
- Leukemia Lymphoma
- Other Rare Blood Disorders Topics
- Type 1 Diabetes
- Other Oncology Topics
- Yellow Fever
- indications.amyotrophic_lateral_sclerosis_als
- Meningococcal disease
- indications.peripheral_arterial_disease
- Other Cardiology Topics
- Hyperkalemia
- Transplant
- indications.post_myocardial_infarction
- Anti Infectives
- Travel
- Other Dermatology Topics
- Hyperuricemia
- indications.dengue_test
- Typhoid
- indications.trachomatis_infections
- Achondroplasia
- indications.diuretic
- Schizophrenia
- Prostate Cancer
- Gastroesophageal Reflux Disease Gerd
- Better Care for Rare
- Dtwcp Hib Ipv Hep B Hexa Whole Cell Primary Series
- Antiparasitic
- Tdap - Booster
- Lung Cancer
- Respiratory Syncytial Virus
- Colorectal Cancer
- Tdacp Ipv Booster
- indications.head_and_neck_cancer
- Haemophilus Influenza
- Scientific Content
- Sitemap
- Sign Up
- Sign In
- Legal notice
- Privacy Policy
- Cookie Policy